Replies to post #82187 on Biotech Values

[masterlongevity]

results almost identical to rituxan. what is the competitive advantage?

Also, who do we know who is working on a rituxan generic and when can we expect it?

[genisi]

GSK/Genmab announced the accelerated approval of Arzerra (ofatumumab) from the FDA for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab.

http://www.reuters.com/article/marketsNews/idCNLR34044920091027?rpc=44